{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:55Z","timestamp":1792715875624,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la Ricerca sul Cancro ETS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009414","name":"Istituto Oncologico Veneto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108551","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:15:09Z","timestamp":1789161309000},"page":"108551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinically actionable genomic alterations in breast cancer brain metastases"],"prefix":"10.1016","volume":"11","author":[{"given":"G.","family":"Griguolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Collesei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lazzarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8098-1819","authenticated-orcid":false,"given":"M.","family":"Bottosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-9861","authenticated-orcid":false,"given":"M.V.","family":"Dieci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fineberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-2496","authenticated-orcid":false,"given":"L.","family":"Bauchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4303-2462","authenticated-orcid":false,"given":"G.","family":"Landa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Miglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Rigau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8412-4926","authenticated-orcid":false,"given":"M.","family":"La Commare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3505-1540","authenticated-orcid":false,"given":"L.","family":"Trov\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-061X","authenticated-orcid":false,"given":"W.","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Dei Tos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-7136","authenticated-orcid":false,"given":"S.","family":"Indraccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1384-1709","authenticated-orcid":false,"given":"A.","family":"Darlix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmoop.2026.108551_bib1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/sj.bjc.6605373","article-title":"Brain metastases admissions in Sweden between 1987 and 2006","volume":"101","author":"Smedby","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108551_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/EDBK_175338","article-title":"Breast cancer in the central nervous system: multidisciplinary considerations and management","volume":"37","author":"Lin","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108551_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-025-00735-w","article-title":"Temporal evolution of breast cancer brain metastases treatments and outcomes","volume":"11","author":"Bottosso","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108551_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102247","article-title":"Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer","volume":"9","author":"Bottosso","year":"2024","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108551_bib5","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108551_bib6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108551_bib7","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/neuonc\/noaa025","article-title":"Estrogen\/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival","volume":"22","author":"Sperduto","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2026.108551_bib8","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108551_bib9","unstructured":"BB-0033-00031\/Lames blanches\/CRB\/ CHU de Montpellier, r\u00e9seau BioBanques; collections \u2018Neurology\u2019 and \u2018CEREMET-LR\u2019 of the Biological Resource Center of Montpellier University Hospital; http:\/\/www.chu-montpellier.fr. Accessed September 6, 2026."},{"issue":"22","key":"10.1016\/j.esmoop.2026.108551_bib10","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108551_bib11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108551_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1200\/PO.19.00345","article-title":"Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity","volume":"4","author":"Sokol","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108551_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2026.108551_bib14","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1038\/ncomms6496","article-title":"BRCA1 haploinsufficiency for replication stress suppression in primary cells","volume":"5","author":"Pathania","year":"2014","journal-title":"Nat Commun"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108551_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2024.42.16_suppl.1021","article-title":"TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2","volume":"42","author":"Tung","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108551_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105507","article-title":"Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications","volume":"10","author":"Griguolo","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108551_bib17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaoncol.2016.5630","article-title":"Intrinsic subtype switching and acquired ERBB2\/HER2 amplifications and mutations in breast cancer brain metastases","volume":"3","author":"Priedigkeit","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108551_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102389","article-title":"Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population","volume":"9","author":"Lu","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108551_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41467-022-27987-5","article-title":"Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities","volume":"13","author":"Cosgrove","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108551_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.32540","article-title":"Patterns of recurrence and metastasis in BRCA1\/BRCA2-associated breast cancers","volume":"126","author":"Song","year":"2020","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.esmoop.2026.108551_bib21","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.20.01200","article-title":"Mutations in BRCA1\/2 and other panel genes in patients with metastatic breast cancer\u2014association with patient and disease characteristics and effect on prognosis","volume":"39","author":"Fasching","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108551_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41523-022-00407-z","article-title":"Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer","volume":"8","author":"Garber","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2026.108551_bib23","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1200\/JCO.2021.39.15_suppl.1090","article-title":"Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician\u2019s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial","volume":"39","author":"Litton","year":"2021","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2026.108551_bib24","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108551_bib25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.annonc.2026.05.707","article-title":"Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"de Azambuja","year":"2026","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108551_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3071","article-title":"Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases","volume":"13","author":"Adamo","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108551_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajpath.2013.03.023","article-title":"Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases","volume":"183","author":"Hohensee","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.esmoop.2026.108551_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejca.2017.10.006","article-title":"Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer","volume":"87","author":"Le Rhun","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108551_bib29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jocn.2017.06.004","article-title":"Role for loss of nuclear PTEN in a harbinger of brain metastases","volume":"44","author":"Nosaka","year":"2017","journal-title":"J Clin Neurosci"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108551_bib30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/1535-7163.MCT-10-1089","article-title":"PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer","volume":"10","author":"Gonzalez-Angulo","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108551_bib31","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1186\/bcr3150","article-title":"Relevance of PTEN loss in brain metastasis formation in breast cancer patients","volume":"14","author":"Wikman","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108551_bib32","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.18632\/oncotarget.14047","article-title":"PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression","volume":"8","author":"Hohensee","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108551_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29062-w","article-title":"Buparlisib is a brain penetrable pan-PI3K inhibitor","volume":"8","author":"de Gooijer","year":"2018","journal-title":"Sci Rep"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108551_bib34","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.2024.42.16_suppl.1018","article-title":"Genomic and tumor microenvironment dynamics of brain metastases in breast cancer","volume":"42","author":"Manogna","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108551_bib35","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/neuonc\/noac136","article-title":"A comprehensive profiling of the immune microenvironment of breast cancer brain metastases","volume":"24","author":"Griguolo","year":"2022","journal-title":"Neuro Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108551_bib36","article-title":"33P Breast cancer brain metastases present a suppressed immune microenvironment enriched in macrophagic components as compared to paired primary tumors","volume":"9","author":"Griguolo","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108551_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11060-018-2805-9","article-title":"Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer","volume":"138","author":"Darlix","year":"2018","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108551_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41523-025-00886-w","article-title":"Basal-like HR+\/HER2\u2212 breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications","volume":"12","author":"Griguolo","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108551_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41698-024-00761-0","article-title":"Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors","volume":"8","author":"Giannoudis","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108551_bib40","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108551_bib41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/neuonc\/noz012","article-title":"Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications","volume":"21","author":"Boire","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.esmoop.2026.108551_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104479","article-title":"Clinical applications of radiomics and deep learning in breast and lung cancer: a narrative literature review on current evidence and future perspectives","volume":"203","author":"Ferro","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108551_bib43","article-title":"Ideafix: a decision tree-based method for the refinement of variants in FFPE DNA sequencing data","volume":"3","author":"Tellaetxe-Abete","year":"2021","journal-title":"NAR Genom Bioinform"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:40:52Z","timestamp":1792712452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926024968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926024968"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108551","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically actionable genomic alterations in breast cancer brain metastases","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108551"}}